Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...
Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...
Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...
Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
In a world grappling with an ever-evolving geopolitical crisis, fostering cross-pollination of ideas, research, and policies ...
But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...
Colossal, a leading biosciences company working to combat environmental dangers and revive extinct species, has reached a new ...
Colossal Biosciences, the company that's famously on a mission to bring back the woolly mammoth and two other extinct species ...
Ghanaian-born engineer, inventor, and telecommunications expert, Dr. Victor B. Lawrence, has received the prestigious ...